AHSG, alpha 2-HS glycoprotein, 197

N. diseases: 204; N. variants: 18
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1859878
Disease: Alopecia-Mental Retardation Syndrome 1
Alopecia-Mental Retardation Syndrome 1 		0.500 GeneticVariation disease UNIPROT Association of AHSG with alopecia and mental retardation (APMR) syndrome. 28054173 2017
CUI: C1859878
Disease: Alopecia-Mental Retardation Syndrome 1
Alopecia-Mental Retardation Syndrome 1 		0.500 Biomarker disease CTD_human
CUI: C4551986
Disease: AMR Syndrome
AMR Syndrome 		0.310 Biomarker disease BEFREE Association of AHSG with alopecia and mental retardation (APMR) syndrome. 28054173 2017
CUI: C0006663
Disease: Calcinosis
Calcinosis 		0.310 Biomarker phenotype CTD_human Fetuin-A knockout (fetuin-KO) mice spontaneously develop widespread soft tissue calcification, including significant myocardial calcification, whereas larger arteries are spared. 16177000 2005
CUI: C0006663
Disease: Calcinosis
Calcinosis 		0.310 Biomarker phenotype LHGDN Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. 12207096 2002
CUI: C4551986
Disease: AMR Syndrome
AMR Syndrome 		0.310 Biomarker disease CTD_human
CUI: C0013221
Disease: Drug toxicity
Drug toxicity 		0.300 Biomarker group CTD_human A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers. 28885000 2017
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute 		0.300 Biomarker disease CTD_human A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers. 28885000 2017
CUI: C0041755
Disease: Adverse reaction to drug
Adverse reaction to drug 		0.300 Biomarker group CTD_human A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers. 28885000 2017
CUI: C1565662
Disease: Acute Kidney Insufficiency
Acute Kidney Insufficiency 		0.300 Biomarker disease CTD_human A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers. 28885000 2017
CUI: C2609414
Disease: Acute kidney injury
Acute kidney injury 		0.300 Biomarker disease CTD_human A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers. 28885000 2017
CUI: C2931280
Disease: Perniola Krajewska Carnevale syndrome
Perniola Krajewska Carnevale syndrome 		0.300 GermlineCausalMutation disease ORPHANET Association of AHSG with alopecia and mental retardation (APMR) syndrome. 28054173 2017
CUI: C0263628
Disease: Tumoral calcinosis
Tumoral calcinosis 		0.300 Biomarker disease CTD_human Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. 16177000 2005
CUI: C0521174
Disease: Microcalcification
Microcalcification 		0.300 Biomarker phenotype CTD_human Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. 16177000 2005
CUI: C0002170
Disease: Alopecia
Alopecia 		0.110 Biomarker disease BEFREE Association of AHSG with alopecia and mental retardation (APMR) syndrome. 28054173 2017
CUI: C1833683
Disease: NEPHROLITHIASIS, CALCIUM OXALATE
NEPHROLITHIASIS, CALCIUM OXALATE 		0.110 GeneticVariation disease CLINVAR A whole genome SNP genotyping by DNA microarray and candidate gene association study for kidney stone disease. 24886237 2014
CUI: C1833683
Disease: NEPHROLITHIASIS, CALCIUM OXALATE
NEPHROLITHIASIS, CALCIUM OXALATE 		0.110 GeneticVariation disease BEFREE Fetuin-A c.742C > T and c.766C > G polymorphisms were investigated in 103 patients with calcium oxalate nephrolithiasis and 73 age- and gender-matched healthy volunteers, using polymerase chain reaction-restriction fragment length polymorphism techniques. 19931899 2010
CUI: C0002170
Disease: Alopecia
Alopecia 		0.110 Biomarker disease HPO
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases 		0.100 Biomarker group BEFREE As a multifunctional protein, fetuin-A has positive effects on health such as calcification, cardiovascular diseases and tumor development processes with various mechanisms, whereas it plays a negative role in the processes of obesity, diabetes and fatty liver disease. 31232084 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 AlteredExpression disease BEFREE Affecting the fetuin-A and SIRT1 levels introduces a new known mechanism of probiotic action in diabetes management. 30675190 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 AlteredExpression disease BEFREE <b>Conclusion:</b> Lower fetuin-A levels are associated with an increased risk of all-cause mortality independent of diabetes and inflammation in dialysis patients, and there may be a dose-response relationship between them. 31417425 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE As a multifunctional protein, fetuin-A has positive effects on health such as calcification, cardiovascular diseases and tumor development processes with various mechanisms, whereas it plays a negative role in the processes of obesity, diabetes and fatty liver disease. 31232084 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.100 Biomarker group BEFREE As a multifunctional protein, fetuin-A has positive effects on health such as calcification, cardiovascular diseases and tumor development processes with various mechanisms, whereas it plays a negative role in the processes of obesity, diabetes and fatty liver disease. 31232084 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.100 AlteredExpression group BEFREE <b>Conclusion:</b> Lower fetuin-A levels are associated with an increased risk of all-cause mortality independent of diabetes and inflammation in dialysis patients, and there may be a dose-response relationship between them. 31417425 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.100 AlteredExpression group BEFREE Affecting the fetuin-A and SIRT1 levels introduces a new known mechanism of probiotic action in diabetes management. 30675190 2019